Targeting MET in EGFR resistance in non-small-cell lung cancer-ready for daily practice?

Lancet Oncol. 2020 Mar;21(3):320-322. doi: 10.1016/S1470-2045(19)30859-9. Epub 2020 Feb 3.

¹ Department of Oncology and Hematology, Cantonal Hospital St Gallen, St Gallen, Switzerland; Department of Medical Oncology Lung Unit, Princess Margaret Cancer Centre, Toronto, ON, Canada.
² Department of Oncology and Hematology, Cantonal Hospital St Gallen, St Gallen, Switzerland; Department of Medical Oncology, University of Berne, Berne, Switzerland.
³ Department of Oncology, Centre Hospitalier Universitaire Vaudois, Lausanne University, CH-1011 Lausanne, Switzerland. Electronic address: solange.peters@chuv.ch.

No abstract available

Publication types

Acrylamides
Aniline Compounds
Protein Kinase Inhibitors
Pyrazines
Triazines
1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine
osimertinib
EGFR protein, human
ErbB Receptors